WONDZORG
SECURA◊
Klinische richtlijnen suggereren dat effectieve huidverzorging kan bijdragen aan het verminderen van drukletsel, als onderdeel van een breder zorgplan.1 De SECURA Range is samengesteld om te reinigen, te beschermen en te hydrateren.
Producteigenschappen
Volgens internationale richtlijnen kan preventieve huidverzorging met een pH-gebalanceerde reiniger, beschermer/barrière en vochtinbrenger helpen de huidintegriteit en -hygiëne in stand te houden als onderdeel van een gestructureerd huidverzorgingsprogramma1 ter voorkoming van drukletsel.
Medical Education
No results.
Disclaimers
Disclaimers
*Controleer de beschikbaarheid van elk product uit de SECURA Skincare Range in uw land of regio.
**Zoals aangetoond in een case-serie.
Citations
1. European Pressure Ulcer Advisory Panel, National Pressure Injury Advisory Panel and Pan Pacific Pressure Injury Alliance. Prevention and Treatment of Pressure Ulcers/Injuries: Clinical Practice Guideline. Emily Haesler (Ed.). EPUAP/NPIAP/PPPIA: 2019.
2. Smith+Nephew 2020.The justification of pH buffered claim for the total body foam cleanser (TBFCI). Internal Report
3. Smith+Nephew 2020. Laboratory testing of cleansing claims for the updated formulation of SECURA Total Body Foam Cleanser. Internal Report. RS\20\076
4. Byers PH, Ryan PA, Regan MB, Shields A, Carta SG. Effects of Incontinence Care Cleansing Regimens on Skin Integrity. JWOCN. 1995;22(4):187-192.
5. Smith+Nephew 2020.The justification of the 'saves valuable nursing time. Cost effective - 75% less cleaning time compared to soap and water' claim for the total body foam cleanser (TBFCI). Internal Report.
6. Smith+Nephew 2020.SECURA Total Body Foam Cleanser and SECURA Personal Cleanser. Internal Report. PSS415.
7. Hilltop Research 2007.An Evaluation of Healthcare Products on Children 0 to 36 Months of Age with Normal Skin. Internal Report. 07-128386-111.
8. Smith+Nephew 2020.The justification of the 'CHG compatible' claim for the Total Body Foam Cleanser reformulation. Internal Report.
9. Microbac 2012.Chlorhexidine Gluconate Compatibility Evaluation of Skin Treatment Products. Internal Report. 795-101
10. Title 21 CFR Part 347 - Skin Protectant Drug Products for Over-the-Counter Human Use (Final Monograph, 06/2003)
11. Global Medical Device Nomenclature Code 46206: Skin Protectant, Skin Barrier
12. Skin Protectant Drug Products for Over-the-Counter Human Use: Proposed Rulemaking for Diaper Rash Drug Products, Federal Register, 06/1990
13. Triple Care D Formulation (Swiss American Products).
14. Global Medical Device Nomenclature Code 46206: Skin Protectant, Skin Barrier
15. Study HTR 07-128386-111: An Evaluation of Healthcare Products on Children 0-36 Months of Age with Normal Skin, 11/2007.
16. Health Canada. Diaper Rash Products Monograph. In. Canada: Health Products and Food Branch; 2018
17. Smith+Nephew 2019.Review of MVTR data for No-Sting Skin Prep. Internal Report. RD/19/020.
18. Smith+Nephew 2019.Verification testing of No-Sting Skin Prep usability report. Internal Report. U/059/R5
19. Smith+Nephew 2009.Study to determine the wash-off resistance and durability of a barrier film. Internal Report. S09-58-A.
20. Smith+Nephew 2019.Verification testing of No-Sting Skin Prep water resistance and longevity report. Internal Report. U/059/R2.
21. Cunarro Alonso JM, Martinez Sanchez P, Puerta Morales G. Use of the non-irritating skin protector No Sting Skin Prep in a series of cases in the social health field. Paper presented at: XIII National Symposium on Pressure Ulcers and Wounds Heritage; 2010; Spain.
22. Francisco JGJ, Del Mar AGM, Maria PPJ, et al. Assessment of a new non-irritating skin protector for different skin disorders. Paper presented at: XIII National Symposium on Pressure Ulcers and Wounds Heritage; 2010; Spain.
23. Porras Pastor JM, Roman Manzano A, Jiminez Garcia JF, et al. Effectiveness of a non-irritating skin protectant in a series of clinical cases in primary care. Paper presented at: XIII National Symposium on Pressure Ulcers and Wounds Heritage; 2010; Spain.
24. Segovia Gomez T, Bermejo Martinez M, Montero De La Pena MV, et al. Protection and treatment of perilesional skin at risk from external contaminants or forces with a non-irritating skin protector in hospital patients. Paper presented at: XIII National Symposium on Pressure Ulcers and Wounds Heritage; 2010; Spain.
25. Smith+Nephew 2009.Study to determine the wash-off resistance and durability of a barrier film. Internal Report. S09-58-A.
26. Smith+Nephew 2012.Chlorhexidine gluconate compatibility evaluation of skin treatment products. Internal Report. 795-101.
27. Smith+Nephew 2018.Formulation - No Sting Barrier Film Spray. Internal Document.
28. Smith+Nephew 2018.Formulation - Secura No Sting Barrier Film Swab. Internal Document.
29. Smith+Nephew 2019.Review of No-Sting Skin Prep Drying Time. Internal Report. RD/19/026/v2.
30. Smith+Nephew 2009.Assessment of the tactile characterisation of a film forming barrier. Internal Report.
31. Nursing Care Moisturizing Cream Formulation (F-50).
32. Evaluation of Cumulative Irritation Potential in Humans (21-day), Report # 94- 2404-72A, Hill Top Research.
33. Delayed Contact Sensitization Study (Repeated Patch Method) in the Guinea Pig - Report #93C-21027-00, NAmSA
34. Acute Oral Toxicity Study (FHSA) in the Rat – Report #94T-01784-00, NAmSA.